On Thursday, April 13, 2023, Certis Oncology Solutions (“Certis”), a precision oncology and translational science company focused on combining functional assays and artificial intelligence to advance personalized medicine, announced the launch of CertisAI, a new predictive medicine platform that utilizes big data, statistical algorithms, and machine learning to predict drug efficacy based on gene expression biomarkers. This pan-cancer solution can accelerate drug discovery and companion diagnostics development.
Login Or Register To Read Full Story